Ameloblastoma RNA profiling uncovers a distinct non-coding RNA signature

Abstract

Ameloblastoma of the jaws remains the top difficult to treat odontogenic tumour and has a high recurrence rate. New evidence suggests that non-coding RNAs (ncRNAs) play a critical role in tumourgenesis and prognosis of cancer. However, ameloblastoma ncRNA expression data is lacking. Here we present the first report of ameloblastoma ncRNA signatures. A total of 95 ameloblastoma cases and a global array transcriptome technology covering > 285.000 full-length transcripts were used in this two-step analysis. The analysis first identified in a test cohort 31 upregulated ameloblastomaassociated ncRNAs accompanied by signalling pathways of cancer, spliceosome, mRNA surveillance and Wnt. Further validation in an independent cohort points out the long non-coding (lncRNAs) and small nucleolar RNA (snoRNAs): LINC340, SNORD116-25, SNORA11, SNORA21, SNORA47 and SNORA65 as a distinct ncRNA signature of ameloblastoma. Importantly, the presence of these ncRNAs was independent of BRAF-V600E and SMO-L412F mutations, histology type or tumour location, but was positively correlated with the tumour size. Taken together, this study shows a systematic investigation of ncRNA expression of ameloblastoma, and illuminates new diagnostic and therapeutic targets for this invasive odontogenic tumour.

Ultra‐frequent HRAS p.Q61R somatic mutation in canine acanthomatous ameloblastoma reveals pathogenic similarities with human ameloblastoma

“…This study focused exclusively on candidate genes known to be mutated in AM, [11][12][13][14] and it is possible that other oncogenic or tumour suppressor genes could be mutated in CAA, including noncoding RNAs. 31 Furthermore, these data do not ascertain whether the HRAS p.Q61R mutation acts as a primary or secondary oncogenic driver in CAA. Therefore, additional studies are required, especially considering that the biological effects of RAS mutations (ie, proliferation vs senescence) depend on the level of expression of the mutated allele, among other variables.…”

“…This study focused exclusively on candidate genes known to be mutated in AM, and it is possible that other oncogenic or tumour suppressor genes could be mutated in CAA, including non‐coding RNAs . Furthermore, these data do not ascertain whether the HRAS p.Q61R mutation acts as a primary or secondary oncogenic driver in CAA.…”

Small Nucleolar RNA and Small Nucleolar RNA Host Gene Signatures as Biomarkers for Pancreatic Cancer

“…Therefore, it is quite reasonable to speculate that as the regulator of TRIM25, the expression pattern of SNORD17 may also be sensitive to distinguish the different cancer subtypes. Interestingly, Davanian et al [30] rst identi ed SNORA11 as a distinct ncRNA signature of ameloblastoma. Herein, our methylation correlation analysis showed that SNORD17 and SNORA11 were also negatively correlated with methylation.…”

snoRNAs Offer Novel Insight and Promising Perspectives for Lung Cancer Understanding and Management

“…Alterations in the expression level of snoRNAs have also been associated with cancer. Dysregulation of snoRNA expression has been reported in different types of cancers, from leukemia [26] to carcinoma [27] and even sarcoma [28]. Due to these alterations in snoRNA expression, these small RNAs have been considered as potential biomarkers in cancer for several years.…”